Researchers have developed a fully human antibody that suppressed tumor growth and metastatic spread in preclinical models of ...

In the United States, prostate cancer is a leading cause of cancer-related disease and death in men. About half of prostate ...

More than a third of older men with lower urinary tract symptoms (LUTS) derived little or no benefit from an alpha-blocker ...

Researchers found that one in three men had minimal symptomatic benefits from tamsulosin, the most commonly prescribed medication for older men with a form of urinary tract infections, and suggest ...

One in three men will experience moderate to severe lower urinary tract symptoms in their lifetime, with symptoms including ...

For many men, changes in urination are often dismissed as an inevitable part of ageing. Frequent nighttime trips to the ...

Please provide your email address to receive an email when new articles are posted on . Treatment effects also included a decline in prostate-specific antigen. Findings from the study, which assessed ...

Prostate cancer can be treated with targeted therapies, but there are still opportunities to improve on this approach. MultiValent Biotherapies is going after two validated cancer targets with a ...

AstraZeneca (AZN) on Friday announced that the U.S. Food and Drug Administration approved a label expansion for its anti-tumor agent Truqap (capivasertib) as part of a combination regimen for a type ...

Shares of Alpha Tau Medical rose Wednesday after it said it will collaborate with Tolmar International to bring localized alpha radiation cancer therapy to prostate cancer patients in the United ...

Johnson & Johnson (JNJ) reported late-stage clinical trial results showing that adding its prostate cancer drug apalutamide to hormone therapy before and after surgery improved outcomes for men with ...

Potential of urine liquid biopsy in detecting of clinically relevant genomic alterations in advanced genitourinary cancers. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This ...